SAN DIEGO, May 14, 2013 (GLOBE NEWSWIRE) -- Senté, Inc., a privately held cosmeceutical company engaged in the development of differentiated medical skincare products based on glycoproteins, announced today that it has closed its Series-B financing, raising $2.1 million from a combination of new and existing biotechnology investors. This financing provides Senté with a sizable cash balance to fund continued company growth.
Proceeds from the financing will help Senté, Inc. expand commercial operations, scale development capabilities, and add additional line extensions to its portfolio of differentiated medical grade skincare products.
"We are very pleased to see such strong investor interest in our company from experts in the healthcare and aesthetic field," said Kleanthis G. Xanthopoulos, Ph.D., Senté Co-Founder and Board Member. "Our new investors share our vision of creating unique science based dermatological products that will have profound impacts on the skin, and we very much look forward to working with them on this endeavor."
Senté Dermal Repair Cream features a proprietary formulation of the active ingredient heparan sulfate (HS). HS is the most biologically active of the glycoproteins that reside in human skin. The biologically active glycoproteins used in Senté Dermal Repair Cream help promote cell renewal, facilitate new collagen development, increase skin hydration, gradually lighten the appearance of pigmented lesions and soothe irritated skin.
"It has been our privilege to serve our initial physician clients and their patients," said Faheem Hasnain, Chairman of the Board of Senté, Inc. "Their stories and early signs of success are the primary motivation for our work and we are happy to have assembled such an outstanding group of investors to support our mission. The financial capabilities and strategic aspects of this round will help us take Senté to the next level."
About Senté, Inc.
Senté, Inc. is a privately held cosmeceutical company based in San Diego, California. The company is a recognized leader in the development of innovative and targeted medical skincare products based on glycoproteins. Senté recently launched its first physician dispensed dermatological product, Senté Dermal Repair Cream, which is currently the only cosmeceutical product utilizing heparan sulfate on the market today. Senté is leveraging its expertise in biotechnology to delivering novel products for a variety of dermatological concerns. More information on the company can be found at http://www.sentelabs.com.
CONTACT: Media Contact: Sente, Inc. Aaron Hasnain T (760) 753-5400 C (650) 380-1132 email@example.com